Live Feeds
● LIVE Updated 1h ago · 9 sources tracked

Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck exceeded third-quarter expectations and raised its profit guidance, driven by stronger-than-anticipated sales of immunotherapy Keytruda and its newer injectable form Keytruda Qlex. The company's non-GAAP profit was $2.49 per share, 19.3% above analysts' consensus estimates. Merck's revenue was $18.09 billion, up 4.7% year on year.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Merck's revenue was $18.09 billion, up 4.7% year on year.
  • ✓ Merck's non-GAAP profit was $2.49 per share, 19.3% above analysts' consensus estimates.
  • ✓ Keytruda and Keytruda Qlex sales were $8.6 billion, with Keytruda Qlex sales at $830 million.
🛡️ Source Corroboration: 9 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Merck raised its profit guidance due to stronger-than-expected sales of Keytruda and Keytruda Qlex.

Live updates

  1. Merck tops quarterly estimates, hikes profit outlook

    Merck exceeded third-quarter expectations and raised its profit guidance, driven by stronger-than-anticipated sales of immunotherapy Keytruda and its newer injectable form Keytruda Qlex. The company's non-GAAP profit was $2.49 per share, 19.3% above analysts' consensus estimates. Merck's revenue was $18.09 billion, up 4.7% year on year.

    Why it matters

    Merck's performance is significant as it reflects the company's continued strength in oncology and animal health. The pharmaceutical industry is highly competitive, and Merck's ability to exceed expectations and raise its profit outlook is a positive indicator for investors. Keytruda is a key contributor to Merck's revenue, and the newer injectable form, Keytruda Qlex, has shown strong sales.

    What is confirmed

    • Merck's revenue was $18.09 billion, up 4.7% year on year.
    • Merck's non-GAAP profit was $2.49 per share, 19.3% above analysts' consensus estimates.
    • Keytruda and Keytruda Qlex sales were $8.6 billion, with Keytruda Qlex sales at $830 million.

    What to watch next

    • Merck's full-year revenue guidance
    • Keytruda and Keytruda Qlex sales performance in future quarters
    • Merck's pipeline and portfolio developments
    Sources used for this update (10)
    1. www.cnbc.com — Oil today: Iran, US, crude, wti, brent, trump
    2. CNBC — Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
    3. Bloomberg — Merck Boosts Profit Forecast as Key Medicines Top Estimates
    4. Barchart.com — Dear Merck Stock Fans, Mark Your Calendars for October 29
    5. Seeking Alpha — Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE)
    6. 10TV — Merck: Q3 Earnings Snapshot
    7. www.cnbc.com — Merck (MRK) earnings Q3 2026 - CNBC
    8. finance.yahoo.com — MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
    9. rocketnews.com — Merck tops quarterly estimates, hikes profit outlook as new ...
    10. www.merck.com — Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter ...
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community